Skip to main content

ASCO Highlights

Meeting Highlights Online Only

ASCO Highlights

PD-1 Inhibition with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer

Meeting Highlights Online Only

ASCO Highlights

Black Patients with Cancer and COVID-19 More Likely Than White Patients to Have Therapy Disruptions

Meeting Highlights Online Only

ASCO Highlights

Trastuzumab Deruxtecan a New Standard for Patients with HER2-Low Metastatic Breast Cancer

Meeting Highlights Online Only

ASCO Highlights

Patients Aged ≥55 Years with Luminal A Breast Cancer Can Safely Avoid Radiation

Meeting Highlights Online Only

ASCO Highlights

ASCO Highlights Innovation as Key to Equitable Cancer Care

Meeting Highlights

Biosimilars, Oncology Pharmacy Programs, ASCO Highlights

Pharmacist-Driven Intervention Significantly Increases Biosimilar Adoption in Clinical Practice

Meeting Highlights

Biosimilars, ASCO Highlights

Oncologists’ Common Misconceptions About Biosimilars Revealed in a Recent Survey

ASCO Highlights, Bladder Cancer

Neoadjuvant Enfortumab Vedotin Therapy Promising in Patients with Muscle-Invasive Bladder Cancer Ineligible for Cisplatin

ASCO Highlights, Bladder Cancer

Sacituzumab plus Pembrolizumab Shows Promising Antitumor Activity in Metastatic Urothelial Cancer

ASCO Highlights, Prostate Cancer, Antiandrogens

Darolutamide plus ADT and Docetaxel Improves Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

1
2
3
4

Page 1 of 5
Results 1 - 10 of 42